Avammune Therapeutics is a drug discovery company focused on immuno-oncology and especially the STING pathway. Avammune is developing a multimodal approach to modulate the STING pathway to treat cancer. Our multimodal approach employs a combination of engineered viruses and small molecules.
Arun is the Founder and CEO at Avammune Therapeutics. He previously co-founded Aten Porus Lifesciences, Oraxion Therapeutics and Avaliv Therpaeutics, R&D companies focused on drug discovery. Arun was instrumental in the licensing of Oraxion’s technology platform to a US based biotech company for $125 MM. Arun holds an MBA from the Royal Melbourne Institute of Technology (Australia), and a Bachelor of Science degree from Christ University (India). Arun has over 10 years of experience as an entrepreneur in various aspects of business including Finance, Operations, Technology transfer and Business development.
Aditya is the Founder and CSO at Avammune Therapeutics. He previously co-founded Aten Porus Lifesciences, Oraxion Therapeutics and Avaliv Therapeutics, R&D companies focused on drug discovery. Aditya is the inventor of Oraxion’s technology platform that was eventually licensed to a US based biotech company for $125 MM. He has co-authored >15 papers and filed several international patents in the areas of nucleic acid delivery, Niemann-Pick Type C therapeutics, and drug discovery. He has been a recipient of scholarships during his Masters and PhD and was also awarded the H. C. Brown Award for Outstanding Organic Research at Purdue University in June 2012. Aditya has a PhD in Bioorganic Chemistry from Purdue University (USA), MS in Chemical Biology from Leeds University (UK), and B.Sc in Chemistry from Christ University (India).
Srinivasan is the Founder and Director at Avammune Therapeutics. He previously co-founded Aten Porus Lifesciences an Oraxion Therapeutics, both R&D companies focusesd on drug discovery. He is currently serving as the CEO of Porus Labs, a chemical manufacturing conglomerate serving customers across India, US, and Europe. Srinivasan has over 10 years of experience in varied aspects of business including technology transfer, SCM, Business Development and Finance. Srinivasan has an MS in Pharmaceutics from Northeastern University (USA), and B.Pharm from BITS Pilani (India).
STING plays an important role in innate immunity and induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. The activation of Type I Interferons & cytokines further recruits T cells, dendritic cells, macrophages and NK cells that leads to destruction of the infected cells.
Avammune’s approach for the activation of the STING pathway involves a combination of engineered viruses and small molecules for sustained induction of an anti-tumour immune response.
Feel free to email us if you are interested in the project and you want to know more, or to just say hello !